EP1208221A2 - Screening nach inhibitoren der lumazinsynthase - Google Patents

Screening nach inhibitoren der lumazinsynthase

Info

Publication number
EP1208221A2
EP1208221A2 EP00960438A EP00960438A EP1208221A2 EP 1208221 A2 EP1208221 A2 EP 1208221A2 EP 00960438 A EP00960438 A EP 00960438A EP 00960438 A EP00960438 A EP 00960438A EP 1208221 A2 EP1208221 A2 EP 1208221A2
Authority
EP
European Patent Office
Prior art keywords
dimethyl
ribityllumazine
phosphate
synthase
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00960438A
Other languages
English (en)
French (fr)
Inventor
Adelbert Bacher
Simone MÖRTL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP1208221A2 publication Critical patent/EP1208221A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
    • C12N15/8274—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for herbicide resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase

Definitions

  • the invention relates to a method for screening for inhibitors of the biosynthesis of riboflavin. It further relates to plant-type enzymes for said method as well as DNA coding for said enzymes. Finally it relates to a method of inhibiting the biosynthesis of riboflavin in plants as well as chemical compounds exhibiting such inhibition.
  • a promising new approach for finding novel types of herbicides consists in screening libraries of chemical test samples for compounds that inhibit an enzyme in a biochemical pathway that is essential for plants but not for humans or animals.
  • a most promising biosythetic pathway of this type is the pathway of riboflavin biosynthesis.
  • All cellular organisms require riboflavin as an indispensible component of numerous redox enzymes many of which are crucial for the metabolism.
  • All plants generate riboflavin biosynthetically, whereas all animals require a nutritional source of riboflavin. Therefore, an inhibitor for an enzyme in the biosynthesis of riboflavin in plants would not interfere with the metabolism of animals.
  • the absolute amount of riboflavin for cellular activity is low. Therefore, only small amounts of the enzymes for riboflavin biosynthesis are found in cells. This in turm means that only small amounts of an inhibitor for such an enzyme would be-required.
  • the biosynthetic pathway of riboflavin (Fig. 1 ) has been studied in considerable detail in bacteria and yeast.
  • the biosynthetic formation of one molecule of riboflavin (7) requires one molecule of GTP and two molecules of ribulose 5-phosphate.
  • GTP (1 ) is initially converted to the committed product, 2,5-diamino-6-ribosylamino-4(3H)-pyrimidinedione (3) by a sequence of deamination, side chain reduction, and dephosphorylation.
  • the compound (3) is converted to 6,7-dimethyl-8-ribityllumazine (4) by condensation with 3,4- dihydroxy-2-butanone 4-phosphate (5) wich is obtained enzymatically from ribulose 5-phosphate (6) .
  • step (e) determining the presence of inhibition of 6,7-dimethyl-8-ribityllumazine synthase by observation of whether the level detected in step (d) is lower that the level detected in step (b) .
  • step (e) determining the presence of resistance to inhibition of 6,7-dimethyl-8- ribityllumazine synthase by observation of whether the level detected in step (d) is similar to the level detected in step (b). Based on the screening method we have thus provided a general solution of the problem of providing inhibitors as well as a method of inhibition for riboflavin biosynthesis in plants.
  • E. coli ribE protein was similar over its entire length to the sequence predicted by the Arabidopsis gene F6E1 3.1 8.
  • the putative lumazine synthase gene of Arabidopsis also specifies an N-terminal peptide sequence with a high content of serine and threonine (about 67 amino acids) which is devoid of similarity to any sequence in the database and has no equivalent in the E. coli protein.
  • Originator for the construction of an expression vector is cDNA.
  • the ribE gene is amplified by PCR with specific primers and cDNA from the corresponding plant as template. Alternatively the cDNA may originate from an existing EST-clone.
  • the RibE protein of A. thaliana includes a signal sequence of about 67 amino acids which was found not to be essential for enzyme activity.
  • the amplified DNA fragment is modified by two consecutive PCR amplifications with modifying primers. In the first PCR reaction a ribosomal binding site preceding the start codon at an optimal distance is introduced at the 5 ' -end.
  • a recognition site for a restriction enzyme, for example BamHI, Sail or Pstl is introduced at the 3 ' -end.
  • the preferred recognition site is BamHI .
  • the product of the first is used as template.
  • a recognition site for the restriction enzyme EcoRI preceding the ribosomal binding site is introduced with a modifying primer.
  • the amplified DNA fragment is inserted into a vector capable of autonomous replication in the host microorganism to give a recombinant piasmid containing said DNA.
  • the recombinant piasmid is used to transform the host microorganism, for example Escherichia coli or Bacillus subtilis.
  • the preferred host is E. coli.
  • the expression of plant protein may be poor in the host organism.
  • the recombinant piasmid may include a gene or a part of a gene without a stop codon preceding the ribE gene in the same reading frame.
  • a preferred gene for this purpose is the malE gene from E. coli.
  • the expression of such a recombinant DNA generates a fusion protein between the maltose binding protein (MBP) from E. coli and the plant RibE protein.
  • MBP maltose binding protein
  • Fig. 3A shows a construct with putative signal sequence S
  • Fig. 3B shows a construct without the putative signal sequence
  • Fig. 3C shows a construct with maltose binding protein and without putative signal sequence.
  • the strains harbouring the expression vectors can be cultivated in conventional culture media at 1 5 to 40°C.
  • the preferred temperature is 37°C.
  • the E. coli strains are induced with 0.5 to 2 mM isopropyl- ⁇ -D-thiogalactosid at an optical density from 0.5 to 0.8.
  • the cells are incubated between 2 and 1 2 h, preferably 5 h.
  • the cells are lysed with lysozyme and/or disrupted with a sonifier.
  • the crude extract with MBP-ribE fusion protein is purified by affinity chromatography with an amylose resin. A protein is obtained which has the proper folding structure for exhibiting the desired enzyme activity.
  • Lumazine synthase catalyzes the formation of 6,7-dimethyl-8-ribityllumazine by condensation of 5-amino-6-ribitylamino-2,4(1 H,3H)pyrimidinedione with 3,4- dihydroxy-2-butanon 4-phosphate (Neuberger et al., 1 986; Volk & Bacher, 1 988) .
  • the enzyme requires no cofactors and shows full catalytic activity in the presence of a chelator such as EDTA.
  • 3,4-dihydroxy-2-butanon 4-phosphate is prepared enzymatically from ribulose 5-phosphate by the action of 3,4- dihydroxy-2-butanon 4-phosphate synthase (Richter et al., 1 992) .
  • the assay can be started by adding one of the needed substances to a mixture of the others.
  • 5-amino-6-ribitylamino-2,4(1 H,3H)pyrimidinedione is added to a solution of 3,4-dihydroxy-2-butanon 4-phosphate and enzyme in a buffer at pH 6.5 to 8.0, preferably 7.0.
  • the reaction mixture can be incubated for 1 to 60 min at 1 0 to 40°C. Preferably it is incubated for 5 min at 37°C.
  • the assay can be stopped by denaturing the enzyme with trichloroacetic acid, acetone or sodium dodecylsulfate. The preferred denaturing is with trichloroacetic acid.
  • the assay is carried out with otherwise identical mixtures with and without test sample of a possible inhibitor.
  • the enzyme product 6,7-dimethyl-8- ribityllumazine can be detected directly without derivatization, preferably photometrically, preferentially after purification by HPLC.
  • the lumazine can be identified by absorbance at 410 nm.
  • the extinction coefficient is 1 0300 M "1 cm "1 .
  • the product can also be monitored fluorometrically at an absorbance wavelength at 408 nm and an emision wavelength at 487 nm.
  • 6,7- Dimethyl-8-ribityllumazine can also be synthesized without enzymatic catalysis (Bacher et al., 1 996) .
  • the isolated DNA codes specifically for a protein with a plant-type sequence of 6,7- dimethyl-8-ribityllumazine synthase whereby it may have either a single open reading frame for said protein or additionally at least one further open reading frame coding for another enzyme of the flavin pathyways.
  • plant-type sequence means in one sense a sequence as it occurs in a plant (with or without leader sequence). In a broader and more adequate sense, it means a sequence of a sequence space which is established by using a specific plant 6,7-dimethyl-8-ribityllumazine synthase (with or without leader sequence) as a reference sequence, producing an alignment of said reference sequence with at least one other plant 6,7-dimethy!-8-ribityllumazine synthase sequence and obtaining for each position in said alignment a set of equivalent amino acids from the variability at this position. Any sequence contained in this sequence space has a very high likelihood of being functional for the intended enzyme activity and being highly homologous to plant enzymes.
  • a specific plant enzyme may be used selected in accordance with the plant(s) targeted. It is also possible to construct a plant-type enzyme sequence (with or without leader sequence) which is on average closest to each of a subset of plant enzyme sequences of a set of plants targeted.
  • Example 1 Construction of an expression clone
  • the putative ribE gene (gene F6E1 3.1 8) of E. coli was amplified by PCR using a cDNA library (Minet et al.) as template First PCR:
  • the reaction mixtures contained 1 0 pmol primer 5 ' -GfGAGAAATTAACCA TGAAGT-CATTAGCTTCGCCG-3 ' , 1 0 pmol primer 5 ' -TCATGTGGATCCA TGGAACGAGCCGAG-3 ' , 1 0 ng of cDNA, 1 ⁇ l Taq polymerase, 1 0 ⁇ l of buffer (Eurogentec), 6 ⁇ l MgCI 2 (25 mM, Eurogentec) and 20 nmol of dNTPs in a total volume of 1 00 ⁇ l.
  • the mixture was denatured at 94°C for 5 min. 30 PCR cycles (60 sec at 95 °C, 45 sec at 50°C, 45 sec at 72°C) were performed. After another 7 min incubation at 72°C, the mixture was cooled at 4 °C, and the DNA was electrophoresed on a 0.8 % agarose gel. The band at 750 bp was purified with a gel extraction kit (Qiagen) . The DNA fragment was excised from the agarose gel with a scalpel. Three volumes of buffer QX1 (Qiagen) were added to 1 volume of the excised gel and incubated at 50°C for 1 0 min. One gel volume of isopropanol was added.
  • the sample was applied to a Qiaquick column and centrifuged for 1 min at 1 4000 rpm. The flow through was discarded. 0.75 ml buffer PE (Qiagen) were added to the column and centrifuged as before. The flow through was discarded and the column was centrifuged for an additional 1 min at 1 4000 rpm. The column was placed in a clean 1 .5 ml Eppendorf tube. 50 ⁇ l of H 2 0 (bidestilled, sterile) were added to the column and it was centrifuged for 1 min at 1 4000 rpm. The flow through contained the purified DNA.
  • H 2 0 bidestilled, sterile
  • the PCR product and the piasmid pNCO 1 1 3 were digested with the restriction enzymes EcoRI and BamHI, 20 ⁇ l OPA buffer (Pharmacia), 2 ⁇ l EcoRI (20 U, Pharmacia), 2 ⁇ l BamHI (20 U, Pharmacia), 2,5 ⁇ g PCR2 product resp. 5.0 ⁇ g pNCO 1 1 3 in a total of 1 00 ⁇ l H 2 0) at 37°C for 4 h and purified with a PCR purification kit.
  • the digested PCR2 product and the piasmid pNCO 1 1 3 were ligated together with T 4 -ligase yielding piasmid pNCO ⁇ bE(AT): 50 fmol of pNCO 1 1 3, 1 00 fmol of PCR2 product, 4 ⁇ l of buffer (Gibco), and 1 ⁇ l of T 4 - ligase ( 1 U, Gibco) in a total of 20 ⁇ l.
  • the mixture was incubated overnight at 4°C, purified with a PCR purification kit and transformed into electrocompetent E. coli XL-1 Blue cells (Bullock et al., 1 987) by electroporation.
  • the cells were pelleted two times as described before and the pellet was resuspended the first time in 0.5 liter and the second time in 20 ml of ice-cold 1 0 % glycerol. The cells were again pelleted, and the pellet was resuspended to a final volume of 2 to 3 ml in ice-cold 1 0 % glycerol. The suspension was frozen in aliquots of 80 ⁇ l and stored in liquid nitrogen.
  • Electro-transformation using the Gene Pulser apparatus from Biorad The electrocompetent cells were thawed at room temperature and placed on ice. 40 ⁇ l of the cell suspension were mixed with 1 ⁇ l of the ligation mixture and transferred into a sterile 0.2 cm cuvette (Biorad) . The suspension was shaked to the bottom and the cuvette was placed into the chamber slide. The chamber slide was pushed into the chamber and a pulse was applied (2,50 kV, 25 ⁇ F, Pulse Controller 200 Ohm).
  • the cuvette was removed from the chamber and the cells were suspended in 1 ml Soc medium (2 % casein hydrolysate, 0.5 % yeast extract, 1 0 mM NaCI, 2.5 mM KCI, 1 0 mM MgCI 2 , 1 0 mM MgS0 4 , 20 mM glucose) .
  • the suspension was incubated with shaking for 1 h at 37 °C and plated on LB media supplemented with 1 50 mg ampicillin per liter. Plasmids from different clones were isolated (pNCOribE(AT) 1 -1 0) .
  • the plasmids were isolated from 5 ml of fresh ovemiglit culture using the mini piasmid isolation kit from Qiagen.
  • the bacterial pellet was resuspended in 0.3 ml of 50 mM Tris hydrochloride, pH 8.0 containing 1 0 mM EDTA and 1 00 ⁇ g/ml RNase.
  • 0.3 ml of 200 mM sodium hydroxide containing 1 % SDS were added, and the mixture was incubated for 5 min at room temperature.
  • 0.3 ml of chilled 3.0 M sodium acetate, pH 5.5 were added, and the mixture was incubated on ice for 1 0 min.
  • the mixture was centrifuged for 1 5 min at 1 4000 rpm in a minifuge.
  • the supernatant was removed and applied to a Qiagen-tip 20 which was previously equilibrated with 1 ml of 50 mM MOPS , pH 7.0, containing 750 mM NaCI, 1 5 % ethanol and 0.1 5 % Triton X-1 00.
  • the Qiagen tip was washed 4 times with 1 ml of 50 mM MOPS, pH 7.0 containing 1 000 mM NaCI and 1 % ethanol.
  • the DNA was eluted with 0.8 ml of 50 mM Tris hydrochloride, pH 8.5 containing 1 250 mM NaCI and 1 5 % ethanol.
  • the DNA was precipitated with 0.7 volumes of isopropanol, centrifuged at 1 4000 rpm for 30 min and washed with 1 ml cold 70 % ethanol.
  • the DNA sequence of the recombinant plasmids were determined by a automated dideoxynucleotide sequencing methode using an ABI Prism 377 DNA sequencer from Applied Biosystems Inc. with the ABI Prism Sequencing Analysis Software.
  • the ribE gene with the exception of the first 21 6 bp coding for a putative transit peptide was amplified by PCR using piasmid pNCOribE(AT) 1 (from A. thaliana ribE expression clone ) as template. Piasmid pNCOribE(AT) 1 was isolated as described. Amino acid 73 was mutated from an arginine to methionine and a recognition site for the restriction enzyme EcoRI preceding the start codon was introduced at the 5 ' end with a modifying primer.
  • the reaction mixtures contained 1 0 pmol primer 5 ' -
  • TCATGTGGATCCATGGAACGAGCCGAG-3 ' 1 0 ng of cDNA, 1 ⁇ l Taq polymerase (1 U), 1 0 ⁇ l of buffer (Eurogentec), 6 ⁇ l of MgCI 2 (25 mM,
  • the mixture was denatured at 94°C for 5 min. 30 PCR cycles (60 sec at 94°C,
  • the ribE gene with the exception of the first 21 6 bp was amplified by PCR using piasmid pNCOribE(AT) as template and was ligated in frame at the 3 ' -end of the malE gene.
  • the reaction mixtures contained 1 0 pmol primer 5 '-
  • ATAATAATAGCGGCCGCTATGCATGT-TACGGGGTCTCTTATC -3 ' 1 0 pmol primer 5 ' -TCATGTGGATCCATGGAACGAGCCGAG-3 ' , 1 0 ng of cDNA, 1 ⁇ l Taq polymerase ( 1 U), 1 0 ⁇ l of buffer (Eurogentec), 6 ⁇ l MgCI 2 (25 mM, Eurogentec) and 20 nmol of dNTPs in a total volume of 100 ⁇ l.
  • the mixture was denatured at 94°C for 5 min. 30 PCR cycles (60 sec at 94° C, 45 sec at 50° C, 45 sec at 72°C) were performed. After another 7 min incubation at 72° C, the mixture was cooled at 4° C, and the DNA was electrophoresed on a 0.8 % agarose gel. The band at 500 bp was purified with a gel extraction kit (Qiagen) .
  • PCR1 product and 20 nmol dNTPs in a total volume of 1 00 ⁇ l.
  • the mixture was denatured at 94° C for 5 min. 30 PCR cycles (60 sec at 94° C,
  • Piasmid pNCOmalEribH (Fischer, 1 997) was isolated from 20 ml of a overnight culture as described for piasmid pNCO 1 1 3.
  • the PCR product and the piasmid pNCOmalEribH were digested with the restriction enzymes Notl and BamHI (1 0 ⁇ l BamHI buffer (NEB), 1 ⁇ l BSA (1 00x), 4 ⁇ l BamHI (20 U, NEB), 3 ⁇ l Notl (60 U, NEB), 2 ⁇ g PCR product resp. 5 ⁇ g pNCOmalEribH in a total volume of 1 00 ⁇ l) at 37° C for 3 h.
  • the PCR product was purified with a PCR purification kit (Qiagen) .
  • the digested piasmid was electrophoresed on an agarose gel.
  • the cells were thawed in 20 ml 50 mM potassiumphosphate pH 7.0 containing 1 mM EDTA and 0.5 mM phenylmethylsulfonyl fluoride.
  • the mixture was sonified 6 x 1 5 sec (Branson sonifier level 4) .
  • the suspension was centrifuged at 1 5000 rpm at 4°C for 20 min.
  • the supernatant was applied to a 20 ml column of Sepharose Q (Pharmacia) previously equillibrated with 50 mM potassium phosphate pH 7.0 (buffer A) , the column was washed with 60 ml buffer A and developed with a linear gradient of 200 ml buffer A containing 1 M NaCI.
  • Fractions containing the ribE protein were identified by SDS eiectrophorese and concentrated with a Amicon cell (membran size, 30 kDa) . Aliquots containing 5 mg protein were passed through a Superdex 200 (1 .6 by 60 cm, Pharmacia) gel filtration column , which was developed with buffer A containing 1 00 mM NaCI. 38 mg ribE(AT) resp. 2 mg ribE(AT)-sig were obtained.
  • 0.5 I Luria Bertani (LB) medium containing 75 mg ampicillin were inoculated with 40 ml overnight culture of E. coli strain XL-1 harboring piasmid pNCOmalEribE(AT) .
  • the culture was grown in shaking culture at 37°C. At an optical density (600 nm) of 0.5 the culture was induced with 1 mM IPTG. The culture was incubated with shaking for another 3 h.
  • the cells were harvested by centrifugation for 20 min at 5000 rpm and 4°C. The cells were washed with 0.9 % NaCI solution, centrifuged as above and stored at -20°C.
  • the cells were thawed in 1 0 ml 50 mM potassium phosphate, pH 7.0 containing 1 mM EDTA and 0.5 mM phenylmethylsulfonyl fluoride.
  • the mixture was sonified 6 x 1 5 sec (Branson sonifier level 4) .
  • the suspension was centrifuged at 1 5000 rpm at 4°C for 20 min.
  • the supernant was diluted 1 :5 with buffer A (Example 4) and placed on a 2 ml column of amylose resin (New England Biolabs) previously equilibrated with 1 5 ml buffer A. The column was washed with 30 ml buffer A.
  • the fusion protein was eluted from the column with 6 ml buffer A containing 1 0 mM maltose. 5 mg malE-ribE protein was obtained. The purity of the protein (56 kDa) was examined by SDS electrophorese.
  • Example 6 Screening for lumazine synthase activity
  • a reaction mixture contained 1 00 mM potassium phosphate pH 7.5, 20 mM MgCI 2 , 1 0 mM ribose 5-phosphate (Sigma) and 0.1 U pentose-phosphate isomerase (Sigma) and 3,4-dihydroxy-2-butanon 4-phosphate synthase (2000 U) in a total volume of 1 00 ⁇ l.
  • the mixture was incubated at 37 °C for 20 min.
  • Assay mixture contained 1 00 mM potassium phosphate, pH 7.0, 20 mM EDTA, 1 mM 3,4-dihydroxy-2-butanone 4-phosphate, and 5 fi ⁇ of the enzyme sample in a total volume of 50 ⁇ l. After a preincubation time of 2 min at 37°C the reaction was started by the addition of 1 ⁇ l of 5 mM 5-amino-6-ribitylamino-2,4( 1 H,3H)- pyrimidinedione and the samples were incubated at 37°C for 5 min. The reaction was stopped by the addition of 50 ml trichloroacetic acid (1 5 %) .
  • 6,7- Dimethyl-8-ribityllumazine was determined by reverse-phase HPLC on a column of Nucleosil RP1 8.
  • the eluent contained 30 mM formic acid and 20 % methanol.
  • the effluent was monitored fluorometrically (excitation, 408 nm; emission, 487 nm) .
  • One unit of enzyme activity catalyzes the formation of 1 nmol of 6,7-dimethyl-8-ribityllumazine per h at 37°C.
  • the screening for inhibition of lumazine synthase was done with the ribE gene product without the putative transit peptide sequence.
  • the assays were performed with different inhibitor concentrations at constant concentrations of 5-amino-6-ribitylamino-2,4(1 H,3H)pyrimidindione, and 3,4-dihydroxy-2-butanone 4-phosphate.
  • the amount of biomimetically formed lumazine was substracted from the total amount of lumazine.
  • XL-1 Blue a high efficiency transforming recA Escherichia coli strain with ⁇ -

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP00960438A 1999-09-03 2000-08-10 Screening nach inhibitoren der lumazinsynthase Withdrawn EP1208221A2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19942175 1999-09-03
DE1999142175 DE19942175A1 (de) 1999-09-03 1999-09-03 Methode zum Auffinden von Inhibitoren der Riboflavinbiosynthese
PCT/EP2000/007796 WO2001018233A2 (en) 1999-09-03 2000-08-10 Screening for inhibitors of lumazine synthase

Publications (1)

Publication Number Publication Date
EP1208221A2 true EP1208221A2 (de) 2002-05-29

Family

ID=7920749

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00960438A Withdrawn EP1208221A2 (de) 1999-09-03 2000-08-10 Screening nach inhibitoren der lumazinsynthase

Country Status (4)

Country Link
EP (1) EP1208221A2 (de)
AU (1) AU7274800A (de)
DE (1) DE19942175A1 (de)
WO (1) WO2001018233A2 (de)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6146866A (en) * 1997-08-15 2000-11-14 E.I. Du Pont De Nemours And Company Lumazine synthase and riboflavin synthase
CN1289369A (zh) * 1998-01-30 2001-03-28 诺瓦提斯公司 植物核黄素生物合成基因及其用途
JP2000152791A (ja) * 1998-11-11 2000-06-06 E I Du Pont De Nemours & Co ルマジンシンターゼおよびリボフラビンシンターゼ
AU1979500A (en) * 1998-12-15 2000-07-24 Adelbert Bacher Method for screening for inhibitors of riboflavin biosynthesis
DE19903736A1 (de) * 1999-01-30 2000-08-03 Adelbert Bacher Inhibitoren der Biosynthese von Vitamin B2 und Verfahren zu ihrer Herstellung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0118233A3 *

Also Published As

Publication number Publication date
WO2001018233A2 (en) 2001-03-15
AU7274800A (en) 2001-04-10
DE19942175A1 (de) 2001-03-08
WO2001018233A9 (en) 2002-09-06
WO2001018233A3 (en) 2001-05-17

Similar Documents

Publication Publication Date Title
EP3929283A1 (de) Polymerasevarianten
KR20200010285A (ko) 증가된 nadph를 유도하는 생합성 경로의 게놈 공학
EP0967281B1 (de) 3,4-Dihydroxy-2-butanone 4-Phosphate Synthase
JP2006503568A (ja) 修飾されたｃ末端を有するフィードバック耐性ホモセリントランススクシニラーゼ
Varadarajan et al. An engineered protease that cleaves specifically after sulfated tyrosine
KR20230112679A (ko) 아이소프레노이드 측쇄가 있는 사이토키닌을 생산할 수 있는 유전자 조작된 세균
EP1208221A2 (de) Screening nach inhibitoren der lumazinsynthase
WO2006085535A1 (ja) テトラヒドロビオプテリン生合成酵素を用いたビオプテリン類の製造方法
JP3844082B2 (ja) 耐熱性ホタルルシフェラーゼ、耐熱性ホタルルシフェラーゼ遺伝子、新規な組み換え体ｄｎａ及び耐熱性ホタルルシフェラーゼの製造法
US7198932B1 (en) Gdp-4-keto-6-deoxy-d-mannose-3,5-epimerase-4-reductase gene derived from arabidopsis thaliana
Brodegger et al. Novel thioredoxin targets in Dictyostelium discoideum identified by two-hybrid analysis: interactions of thioredoxin with elongation factor 1a and yeast alcohol dehydrogenase.
WO2012043601A1 (ja) アマドリアーゼ改変体
JP4752026B2 (ja) 新規なピリドキサール４−デヒドロゲナーゼ及びその利用
US6399352B1 (en) Plant porphobilinogen synthase and fusion protein thereof
JP2023527107A (ja) シスチンを生体触媒還元するための酵素的触媒酸化還元系のコア構成成分としての生体触媒
JP2000152791A (ja) ルマジンシンターゼおよびリボフラビンシンターゼ
JPH06292584A (ja) 変異型ピルビン酸脱水素酵素複合体のｅ１蛋白質 遺伝子及び変異型ピルビン酸脱水素酵素複合体のｅ１蛋白質
US20020119506A1 (en) Genes encoding UMP kinase, methods for purifying UMP kinase and methods of characterizing UMP kinase
US20240247241A1 (en) Taq enzyme mutant, preparation method, and application thereof
Tiedeman et al. Isolation and characterization of regulatory mutations affecting the expression of the gua BA operon of Escherichia coli K-12
JP4415247B2 (ja) 新規なグリセロールキナーゼ、該遺伝子及び該遺伝子を用いたグリセロールキナーゼの製造法
Amin et al. Importance of the region around lysine 196 for catalytic activity of adenylyl cyclase from Escherichia coli.
US20060166313A1 (en) Novel glycero kinase, gene thereof and process for producing the glycerol kinase by using the gene
JP2002534094A (ja) リボフラビン生合成の阻害剤のためのスクリーニング方法
Jiwaji Regulation of hyu gene expression in Agrobacterium tumefaciens strains RU-AE01 and RU-OR

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020227

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20040802

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20041213